BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16923114)

  • 1. A case of myelofibrosis with myeloid metaplasia with JAK2(V617F) mutation who developed fibrous tumours in multiple organs.
    Tabuchi T; Ohashi H; Fukami S; Susaki N; Kunishima S; Yokozawa T; Nagai H; Moritani S; Ichihara S; Saito H; Hamaguchi M
    Eur J Haematol; 2006 Sep; 77(3):264-6. PubMed ID: 16923114
    [No Abstract]   [Full Text] [Related]  

  • 2. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
    Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; Tefferi A
    Haematologica; 2006 Mar; 91(3):415-6. PubMed ID: 16531268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 mutations in myeloproliferative disorders.
    Tefferi A; Lasho TL; Gilliland G
    N Engl J Med; 2005 Sep; 353(13):1416-7; author reply 1416-7. PubMed ID: 16192494
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lack of association between JAK2 V617F mutation and myelodysplastic syndrome with or without myelofibrosis.
    Yip SF; So CC; Chan AY; Liu HY; Wan TsK; Chan LC
    Leukemia; 2006 Jun; 20(6):1165. PubMed ID: 16572200
    [No Abstract]   [Full Text] [Related]  

  • 9. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.
    Campbell PJ; Griesshammer M; Döhner K; Döhner H; Kusec R; Hasselbalch HC; Larsen TS; Pallisgaard N; Giraudier S; Le Bousse-Kerdilès MC; Desterke C; Guerton B; Dupriez B; Bordessoule D; Fenaux P; Kiladjian JJ; Viallard JF; Brière J; Harrison CN; Green AR; Reilly JT
    Blood; 2006 Mar; 107(5):2098-100. PubMed ID: 16293597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
    Martínez-Avilés L; Besses C; Alvarez-Larrán A; Cervantes F; Hernández-Boluda JC; Bellosillo B
    Haematologica; 2007 Dec; 92(12):1717-8. PubMed ID: 18056003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
    Spivak JL; Moliterno AR; Silver RT
    N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
    [No Abstract]   [Full Text] [Related]  

  • 14. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
    Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
    Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
    Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
    Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
    Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
    Mesa RA; Tefferi A; Lasho TS; Loegering D; McClure RF; Powell HL; Dai NT; Steensma DP; Kaufmann SH
    Leukemia; 2006 Oct; 20(10):1800-8. PubMed ID: 16871275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.